Tools
Stock profile

Ginkgo Bioworks Holdings, Inc. (DNA)

DNA · Latest close $8.44 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$8.44
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

Ginkgo Bioworks Holdings, Inc. (DNA) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Insiders were net sellers over the last 90 days ($0 bought vs $1.4M sold). Latest close $8.44 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 19, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-1.4M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Viking Global Investors · Edgewood Management — 2 tracked funds hold DNA. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 9 sales ($1.4M). Insider trading

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Viking Global Investors0.10%3,577,128HELD Q3 filed Nov 16
Edgewood Management0.01%50,000HELD Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -19.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

16.365.042024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding186 of 8,857 filers
Long-only filers among them184
Change vs 2026 Q1+20 net · 184 entered · 164 exited
Shares reported, all filers35,189,258
Reported value, all filers$354.2M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$170.2M
Net income · FY2025$-312.8M
Total assets · FY2025$1.1B
Shares outstanding63,711,102
Market cap (at latest close)$537.7M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jun 30, 2026.

Short interest

Shares short · Oct 15, 20268,294,322
Share of shares outstanding13.02%
Days to cover1.88

Shares short at recent settlements — Jul 31, 2026: 5.3M · Aug 14, 2026: 5.6M · Aug 31, 2026: 6.9M · Sep 15, 2026: 7.2M · Sep 30, 2026: 7.3M · Oct 15, 2026: 8.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jun 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 4 · Sep 15, 2026: 0 · Sep 30, 2026: 1K · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jun 30, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 9 sales by 5 insiders ($1.4M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 19, 2026Coen Steven P.See remarksSell766$10.14$7.8KSEC filing
Oct 19, 2026Canton BarrySell18,803$10.14$190.7KSEC filing
Oct 19, 2026Canton BarrySell22,369$10.14$226.9KSEC filing
Oct 19, 2026Shetty Reshma P.See remarksSell22,369$10.14$226.9KSEC filing
Oct 19, 2026Shetty Reshma P.See remarksSell18,803$10.14$190.7KSEC filing
Oct 19, 2026Kelly Jason RSee remarksSell45,682$10.14$463.4KSEC filing
Oct 5, 2026Coen Steven P.See remarksSell2,403$15.00$36.0KSEC filing
Sep 15, 2026HENRY CHRISTIAN OSell5,000$7.08$35.4KSEC filing
Aug 24, 2026Coen Steven P.See remarksSell330$6.98$2.3KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 5, 2026Coen Steven P.Officer2,403$36.0KOct 5, 2026SEC filing
Sep 17, 2026Che AustinOfficer2,200$16.0KSep 17, 2026SEC filing
Sep 15, 2026HENRY CHRISTIAN ODirector5,000$35.4KSep 15, 2026SEC filing
Aug 24, 2026Coen Steven P.Officer330$2.3KAug 24, 2026SEC filing
Aug 17, 2026Che AustinOfficer2,200$14.7KAug 17, 2026SEC filing
Jul 17, 2026Coen Steven P.Officer752$5.9KJul 17, 2026SEC filing
Jun 10, 2026Che AustinOfficer2,200$17.7KJun 10, 2026SEC filing
May 22, 2026Coen Steven P.Officer307$2.6KMay 22, 2026SEC filing
May 13, 2026Che AustinOfficer2,200$18.2KMay 13, 2026SEC filing
Apr 17, 2026Coen Steven P.Officer324$2.6KApr 17, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Feb 14, 2025SCHEDULE 13D/A-39.6% (close Feb 18, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Feb 18, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 30, 2026BlackRock, Inc.SC 13G/A4,122,5107.7%Jun 30, 2026SEC filing
May 15, 2026VIKING GLOBAL INVESTORS LPSC 13G/A3,577,1287.1%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 5, 2026BAILLIE GIFFORD & COSC 13G/A2,391,6494.9%Dec 31, 2025SEC filing
Nov 14, 2025Cascade Investment, L.L.C.SC 13G/A3,621,6367.5%Sep 30, 2025SEC filing
Jul 29, 2025The Vanguard GroupSC 13G2,381,1155.1%Jun 30, 2025SEC filing
Jul 17, 2025BlackRock, Inc.SC 13G3,001,6436.5%Jun 30, 2025SEC filing
Feb 14, 2025Austin CheSC 13G/A2,372,5735.0%Dec 31, 2024SEC filing
Feb 14, 2025Reshma P. ShettySC 13D/A4,716,0849.5%Feb 14, 2025SEC filing
Jan 30, 2025The Vanguard GroupSC 13G/A2,013,5484.5%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 73 Lobbying Disclosure Act filings named this company as client, 2019–2026; most common issues: Defense (44), Medical/Disease Research/Clinical Labs (34), Science/Technology (30).

Federal contracts: $100.0M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$0
FY2022$0
FY2023$0
FY2024$67.2M
FY2025$4.0M
FY2026$28.8M

Largest awards collected

Award IDAgencyAmountStart
75D30125C20439Department of Health and Human Services$78.0MFeb 28, 2025
75D30122C14933Department of Health and Human Services$62.6MAug 16, 2022
HR001117C0092Department of Defense$10.4MSep 15, 2017
75N92020C00007Department of Health and Human Services$6.6MJul 30, 2020
HR001120C0073Department of Defense$5.9MSep 16, 2020

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Distress Risk (Altman Z″) — Z″-Score: -13.05 · Working capital / assets: 0.36 · Retained earnings / assets: -4.24 · EBIT / assets: -0.41 · Equity / liabilities: 1.08

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q2, ranked #39 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)10.0%-31.8%+4.4%-36.2%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold DNA — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 29, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on DNA

One email a week: the week’s new filings and research. Subscribe free

← DMRA  ·  DNLI →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.